Albumin as a versatile platform for drug half-life extension

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 12, 2013, Pages 5526-5534

  Sleep, Darrell ^a   Cameron, Jason ^a   Evans, Leslie R ^a  

^a Novozymes Biopharma DK A S   (United Kingdom)

Author keywords

Albumin; Animal models; FcRn; Half life; Pharmacokinetics; Protein drug

Indexed keywords

EID: 84885370061     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2013.04.023     Document Type: Review

References (106)

1. R.E. Kontermann Strategies for extended serum half-life of protein therapeutics Curr. Opin. Biotechnol. 22 2011 1 9
2. T. Peters Jr. All About Albumin 1996 Academic Press Inc. USA 223 234
3. C.L. Anderson, C. Chadhury, J. Kim, C.L. Bronson, M.A. Wani, and S. Mohanty Perspective - FcRn transports albumin: relevance to immunology and medicine Trends Immunol. 27 2006 343 348 (Pubitemid 43963476)
4. J. Kim, W.L. Hayton, J.M. Robinson, and C.L. Anderson Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model Clin. Immunol. 122 2007 146 155 (Pubitemid 46073892)
5. N. Ghinea, A. Fixman, D. Alexandru, D. Popov, M. Hasu, L. Ghitescu, M. Eskenasy, M. Simionescu, and N. Simionescu Identification of albumin-binding proteins in capillary endothelial cells J. Cell Biol. 107 1988 231 239
6. J. Schnitzer, A. Sung, R. Horvat, and J. Bravo Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins J. Biol. Chem. 267 1992 24544 24553
7. J. Schnitzer, and J. Bravo High affinity binding, endocytosis and degradation of conformationally modified albumins J. Biol. Chem. 268 1993 7562 7570
8. J. Schnitzer, and P. Oh Albondin-mediated capillary permeability to albumin J. Biol. Chem. 269 1994 6072 6082
9. R. Minshall, C. Tiruppathi, S.M. Vogel, and A.B. Malik Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function Histochem. Cell Biol. 117 2002 105 112 (Pubitemid 34185616)
10. A.B. Malik Targeting endothelial cell surface receptors: novel mechanisms of microvascular endothelial barrier transport J. Med. Sci. 2 2009 13 17
11. D. Predescu, and G.E. Palade Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium Am. J. Physiol. 265 1993 H725 H733
12. M. Gekle Renal tubules albumin transport Annu. Rev. Physiol. 67 2005 573 594
13. B. Haraldsson, J. Nystrom, and W.M. Deen Properties of the glomerular barrier and mechanisms of proteinuria Physiol. Rev. 88 2008 451 487 (Pubitemid 351522745)
14. M. Sarav, Y. Wang, B.K. Hack, A. Chang, M. Jensen, L. Bao, and R.J. Quigg Renal FcRn reclaims albumin but facilitates elimination of IgG J. Am. Soc. Nephrol. 20 2009 1941 1952
15. D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725 (Pubitemid 47327396)
16. S. Kinugasa, A. Tojo, T. Sakai, H. Tsumura, M. Takahashi, Y. Hirata, and T. Fujita Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase Kidney Int. 80 2011 1328 1338
17. R.J. Baines, and N.J. Brunskill Tubular toxicity of proteinuria Nat. Rev. Nephrol. 7 2011 177 180
18. E.I. Christensen, P.J. Verroust, and R. Nielson Receptor-mediated endocytosis in renal proximal tubule Pflugers Arch. 458 2009 1039 1048
19. N.E. Simister, and K.E. Mostov An Fc receptor structurally related to MHC class I antigens Nature 337 1989 184 187 (Pubitemid 19025381)
20. W.P. Burmeister, L.N. Gastinel, M.L. Blum, and P.J. Bjorkman Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor Nature 372 1994 336 343
21. A.P. West Jr., and P.J. Bjorkman Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor Biochemistry 39 2000 9698 9708 (Pubitemid 30626819)
22. L.N. Gastinel, N.E. Simister, and P.J. Bjorkman Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules Proc. Natl. Acad. Sci. U. S. A. 89 1992 638 642
23. A.R. Mezo, V. Sridhar, J. Badger, P. Sakorafas, and V. Nienaber X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor FcRn J. Biol. Chem. 285 2010 27694 27701
24. J.T. Andersen, J. Dee Qian, and I. Sandlie The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin Eur. J. Immunol. 36 2006 3044 3051 (Pubitemid 44782576)
25. C. Chaudhury, S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Pearl, D.C. Roopenian, and C.L. Anderson The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan J. Exp. Med. 197 2003 315 322 (Pubitemid 36184238)
26. V. Ghetie, J.G. Hubbard, J.K. Kim, M.F. Tsen, Y. Lee, and E.S. Ward Abnormally short serum half-lives of IgG in beta 2-microglobulin deficient mice Eur. J. Immunol. 26 1996 690 696 (Pubitemid 26091401)
27. R.P. Junghans, and C.L. Anderson The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor Proc. Natl. Acad. Sci. U. S. A. 93 1996 5512 5516
28. E.S. Ward, and R.J. Ober Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn Adv. Immunol. 103 2009 77 115
29. J. Kim, C.L. Bronson, W.L. Hayton, M.D. Radmacher, D.C. Roopenian, J.M. Robinson, and C.L. Anderson Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces Am. J. Physiol. Gastrointest. Liver Physiol. 290 2006 G352 G360
30. H.P. Montoyo, C. Vaccaro, M. Hafner, R.J. Ober, W. Mueller, and E.S. Ward Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice Proc. Natl. Acad. Sci. U. S. A. 106 2009 2788 2793
31. M.A. Wani, L.D. Haynes, J. Kim, C.L. Bronson, C. Chaudhury, S. Mohanty, T.A. Waldmann, J.M. Robinson, and C.L. Anderson Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene Proc. Natl. Acad. Sci. U. S. A. 103 2006 5084 5089
32. T.A. Waldmann, and W.D. Terry Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin J. Clin. Invest. 86 1990 2093 2098
33. R. Rodewald pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat J. Cell Biol. 71 1976 666 669
34. W.P. Burmeister, A.H. Huber, and P.J. Bjorkman Crystal structure of the complex of rat neonatal Fc receptor with Fc Nature 372 1994 379 383 (Pubitemid 24363442)
35. C. Medesan, D. Matesoi, C. Radu, V. Ghetie, and E.S. Ward Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1 J. Immunol. 158 1997 2211 2217 (Pubitemid 127470004)
36. P.R. Hinton, J.M. Xiong, M.G. Johlfs, M.T. Tang, S. Keller, and N. Tsurushita An engineered human IgG1 antibody with longer serum half-life J. Immunol. 176 2006 346 356 (Pubitemid 43023280)
37. V. Ghetie, S. Popov, J. Borvak, C. Radu, D. Matesoi, C. Medesan, R.J. Ober, and E.S. Ward Increasing the serum persistence of an IgG fragment by random mutagenesis Nat. Biotechnol. 15 1997 637 640 (Pubitemid 27291163)
38. J. Zalevsky, A.K. Chamberlain, H.M. Horton, S. Karki, I.W. Leung, T.J. Sproule, G.A. Lazar, D.C. Roopenian, and J.R. Desjarlais Enhanced antibody half-life improves in vivo activity Nat. Biotechnol. 28 2010 157 159
39. C. Chaudhury, C.L. Brooks, D.C. Carter, J.M. Robinson, and C.L. Anderson Albumin binding to FcRn: distinct from the FcRn-IgG interaction Biochemistry 45 2006 4983 4990
40. J.T. Andersen, B. Dalhus, J. Cameron, M.B. Daba, A. Plumridge, L. Evans, S.O. Brennan, K.S. Gunnarsen, M. Bjørås, D. Sleep, and I. Sandlie Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor Nat. Commun. 3 2012 610
41. V.E. Kenanova, T. Olafsen, F.B. Salazar, L.E. Williams, S. Knowles, and A.M. Wu Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins Protein Eng. Des. Sel. 23 2010 789 798
42. K. Nakajou, H. Watanabe, U. Kragh-Hansen, T. Maruyama, and M. Otagiri The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants Biochim. Biophys. Acta 1623 2003 88 97 (Pubitemid 37315665)
43. Y. Iwao, M. Anraku, K. Yamasaki, U. Kragh-Hansen, K. Kawai, T. Maruyama, and M. Otagiri Oxidation of Arg-410 promotes the elimination of human serum albumin Biochim. Biophys. Acta 1764 2006 743 749
44. Y. Iwao, M. Hiraike, U. Kragh-Hansen, K. Mera, T. Noguchi, M. Anraku, K. Kawai, T. Maruyama, and M. Otagiri Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin Biochim. Biophys. Acta 1774 2007 1582 1590 (Pubitemid 350235344)
45. W.P. Sheffield, J.A. Marques, V. Bhakta, and I.J. Smith Modulation of clearance of recombinant serum albumin by either glycosylation or truncation Thromb. Res. 99 2000 613 621 (Pubitemid 30642743)
46. Y. Iwao, M. Hiraike, U. Kragh-Hansen, K. Kawai, A. Suenaga, T. Maruyama, and M. Otagiri Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin Biochim. Biophys. Acta 1794 2009 634 641
47. J.T. Andersen, M.B. Daba, and I. Sandlie FcRn binding properties of an abnormal truncated analbuminemic albumin variant Clin. Biochem. 43 2010 367 372
48. R.J. Ober, C.G. Radu, V. Ghetie, and E.S. Ward Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies Int. Immunol. 13 2001 1551 1559 (Pubitemid 33133882)
49. J.T. Andersen, M.B. Daba, G. Berntzen, T.E. Michaelsen, and I. Sandlie Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding J. Biol. Chem. 285 2010 4826 4836
50. J.T. Andersen, and I. Sandlie Extending half-life by indirect targeting of the Neonatal Fc Receptor (FcRn) using a minimal albumin binding domain Drug Metab. Pharmacokinet. 24 2009 318 332
51. B.J. Smith, A. Popplewell, D. Athwal, A.P. Chapman, S. Heywood, S.M. West, B. Carrington, A. Nesbitt, A.D. Lawson, P. Antoniw, A. Eddelston, and A. Suitters Prolonged in vivo residence times of antibody fragments associated with albumin Bioconjug. Chem. 12 2001 750 756 (Pubitemid 32925877)
52. W. Halpern, T.A. Riccobene, H. Agostini, K. Baker, D. Stolow, M.L. Gu, J. Hirsch, A. Mahoney, J. Carrell, E. Boyd, and K. Grzegorzewski Albugranin™, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys Pharm. Res. 19 2002 1720 1729 (Pubitemid 35305525)
53. G.M. Subramanian, M. Fiscella, A. Lamouse-Smith, S. Zeuzem, and J.G. McHutchison Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat. Biotechnol. 25 2007 1411 1419 (Pubitemid 350233139)
54. S.C. Makrides, P.A. Nygren, B. Andrews, P.J. Ford, K.S. Evans, E.G. Hayman, H. Adari, M. Uhlén, and C.A. Toth Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor J. Pharmacol. Exp. Ther. 277 1996 534 542 (Pubitemid 27169101)
55. S. Curry, H. Mandelkow, P. Brick, and N. Franks Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites Nat. Struct. Biol. 5 1998 827 835 (Pubitemid 28402087)
56. P. Home, and P. Kurtzhals Insulin detemir: from concept to clinical experience Expert Opin. Pharmacother. 7 2006 325 343 (Pubitemid 43263250)
57. B. Elsadek, and F. Kratz Impact of albumin on drug delivery - New applications on the horizon J. Control. Release 157 2012 4 28
58. S. Trüssel, C. Dumelin, K. Frey, A. Villa, F. Buller, and D. Neri New strategy for the extension of the serum half-life of antibody fragments Bioconjug. Chem. 20 2009 2286 2292
59. A. Jonsson, J. Dogan, N. Herne, L. Abrahmsén, and P.A. Nygren Engineering of a femtomolar affinity binding protein to human serum albumin Protein Eng. Des. Sel. 21 2008 515 527 (Pubitemid 352019923)
60. M.S. Dennis, M. Zhang, Y.G. Meng, M. Kadkhodayan, D. Kirchhofer, D. Combs, and L.A. Damico Albumin binding as a general strategy for improving the pharmacokinetics of proteins J. Biol. Chem. 277 2002 35035 35043
61. A. Nguyen, A.E. Reyes II, M. Zhang, P. McDonald, W.L. Wong WL, L.A. Damico, and M.S. Dennis The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin Protein Eng. Des. Sel. 19 2006 291 297 (Pubitemid 43999639)
62. L.J. Holt, A. Basran, K. Jones, J. Chorlton, L.S. Jespers, N.D. Brewis, and I.M. Tomlinson Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs Protein Eng. Des. Sel. 21 2008 283-188
63. B.M. Tijink, T. Laeremans, M. Budde, M. Stigter-van Walsum, T. Dreier, H.J. de Haard, C.R. Leemans, and G.A. van Dongen Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology Mol. Cancer Ther. 7 2008 2288 2297
64. R.C. Roovers, T. Laeremans, L. Huang, S. De Taeye, A.J. Verkleij, H. Revets, H.J. de Haard, and P.M.P. van Bergen en Henegouwen Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies Cancer Immunol. Immunother. 56 2007 303 317 (Pubitemid 46035901)
65. D. Lipovšek Adnectins: engineered target-binding protein therapeutics Protein Eng. Des. Sel. 24 2011 3 9
66. C. Herring, and O. Schon AlbudAb™ technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives R. Kontermann, Therapeutic Proteins: Strategies to Modulate their Plasma Half-lives 2012 Wiley-VCH Verlag & Co. KGaA 249 268
67. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
68. N. Giannoukakis CJC-1131 ConjuChem Curr. Opin. Investig. Drugs 4 2003 1245 1249 (Pubitemid 37420113)
69. D. Bosse, M. Praus, P. Kiessling, L. Nyman, C. Andresen, J. Waters, and F. Schindel Phase I comparability of recombinant human albumin and human serum albumin J. Clin. Pharmacol. 45 2005 57 67
70. R. Léger, K. Thibaudeau, M. Robitaille, O. Quraishi, P. van Wyk, N. Bousquet-Gagnon, J. Carette, J.P. Castaigne, and D.P. Bridon Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog Bioorg. Med. Chem. Lett. 14 2004 4395 4398 (Pubitemid 39043956)
71. L.L. Baggio, Q. Huang, X. Cao, and D.J. Drucker An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis Gastroenterology 134 2008 1137 1147 (Pubitemid 351451971)
72. K. Thibaudeau, R. Léger, X. Huang, M. Robitaille, O. Quraishi, C. Soucy, N. Bousquet-Gagnon, P. van Wyk, V. Paradis, J.P. Castaigne, and D. Bridon Synthesis and evaluation of insulin-human serum albumin conjugates Bioconjug. Chem. 16 2005 1000 1008 (Pubitemid 41026186)
73. C.A. Stoddart, G. Nault, S.A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellomo, V. Paradis, P. Liscourt, A. Lobach, M.E. Rivard, R.G. Ptak, M.K. Mankowski, D. Bridon, and O. Quraishi Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice J. Biol. Chem. 283 2008 34045 34052
74. J. Rosenstock, J. Reusch, M. Bush, F. Yang, and M. Stewart Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing Diabetes Care 32 2009 1880 1886
75. W. Wang, Y. Ou, and Y. Shi AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure Pharm. Res. 21 2004 2105 2111 (Pubitemid 40941232)
76. M.K. de Bold, W.P. Sheffield, A. Martinuk, V. Bhakta, L. Eltringham-Smith, and A.J. de Bold Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris Regul. Pept. 175 2012 7 10
77. R.J. Melder, B.L. Osborn, T. Riccobene, P. Kanakaraj, P. Wei, G. Chen, D. Stolow, W.G. Halpern, T.S. Migone, Q. Wang, K.J. Grzegorzewski, and G. Gallant Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice Cancer Immunol. Immunother. 54 2005 535 547
78. C. Sung, B. Nardelli, D.W. LaFleur, E. Blatter, M. Corcoran, H.S. Olsen, C.E. Birse, O.K. Pickeral, J. Zhang, D. Shah, G. Moody, S. Gentz, L. Beebe, and P.A. Moore An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates J. Interferon Cytokine Res. 23 2003 25 36 (Pubitemid 36308059)
79. T. Weimer, W. Wormsbächer, U. Kronthaler, W. Lang, U. Liebing, and S. Schulte Prolonged in-vivo half-life of factor VIIa by fusion to albumin Thromb. Haemost. 99 2008 659 667 (Pubitemid 351694221)
80. H.J. Metzner, T. Weimer, U. Kronthaler, W. Lang, and S. Schulte Genetic fusion to albumin improves the pharmacokinetic properties of factor IX Thromb. Haemost. 102 2009 634 644
81. Y.J. Huang, P.M. Lundy, A. Lazaris, Y. Huang, H. Baldassarre, B. Wang, C. Turcotte, M. Côté, A. Bellemare, A.S. Bilodeau, S. Brouillard, M. Touati, P. Herskovits, I. Bégin, N. Neveu, E. Brochu, J. Pierson, D.K. Hockley, D.M. Cerasoli, D.E. Lenz, H. Wilgus, C.N. Karatzas, and S. Langermann Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin BMC Biotechnol. 8 2008 50
82. B.L. Osborn, L. Sekut, M. Corcoran, C. Poortman, B. Sturm, G. Chen, D. Mather, H.L. Lin, and T.J. Parry Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys Eur. J. Pharmacol. 456 2002 149 158 (Pubitemid 35351748)
83. S.M. Kerry-Williams, S.C. Gilbert, L.R. Evans, and D.J. Balance Disruption of the Saccharomyces cerevisiae YAP3 gene reduces the proteolytic degradation of secreted recombinant human albumin Yeast 14 1998 161 169 (Pubitemid 28062866)
84. A. Duttaroy, P. Kanakaraj, B.L. Osborn, H. Schneider, O.K. Pickeral, C. Chen, G. Zhang, S. Kaithamana, M. Singh, R. Schulingkamp, D. Crossan, J. Bock, T.E. Kaufman, P. Reavey, M. Carey-Barber, S.R. Krishnan, A. Garcia, K. Murphy, J.K. Siskind, M.A. McLean, S. Cheng, S. Ruben, C.E. Birse, and O. Blondel Development of a long-acting insulin analog using albumin fusion technology Diabetes 54 2005 251 258 (Pubitemid 40105120)
85. C.H. Joung, J.Y. Shin, J.K. Koo, J.J. Lim, J.S. Wang, S.J. Lee, H.K. Tan, S.L. Kim, and S.M. Lim Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell Protein Expr. Purif. 68 2009 137 145
86. D. Müller, A. Karle, B. Meissburger, I. Höfig, R. Stork, and R.E. Kontermann Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin J. Biol. Chem. 282 2007 12650 12660 (Pubitemid 47100581)
87. P.J. Yazaki, T. Kassa, C.W. Cheung, D.M. Crow, M.A. Sherman, J.R. Bading, A.L. Anderson, D. Colcher, and A. Raubitschek Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein Nucl. Med. Biol. 35 2008 151 158 (Pubitemid 351200040)
88. L. Evans, M. Hughes, J. Waters, J. Cameron, N. Dodsworth, D. Tooth, A. Greenfield, and D. Sleep The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae Protein Expr. Purif. 73 2010 113 124
89. C.F. McDonagh, A. Huhalov, B.D. Harms, S. Adams, V. Paragas, S. Oyama, B. Zhang, L. Luus, R. Overland, S. Nguyen, J. Gu, N. Kohli, M. Wallace, M.J. Feldhaus, A.J. Kudla, B. Schoeberl, and U.B. Nielsen Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 Mol. Cancer Ther. 11 2012 582 593
90. S. Ikuta, V.T. Chuang, Y. Ishima, K. Nakajou, M. Furukawa, H. Watanabe, T. Maruyama, and M. Otagiri Albumin fusion of thioredoxin-the production and evaluation of its biological activity for potential therapeutic applications J. Control. Release 147 2010 17 23
91. M. Furukawa, R. Tanaka, V.T. Chuang, Y. Ishima, K. Taguchi, H. Watanabe, T. Maruyama, and M. Otagiri Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury J. Control. Release 154 2011 189 195
92. A. Kodama, H. Watanabe, R. Tanaka, H. Tanaka, V.T. Chuang, Y. Miyamoto, Q. Wu, M. Endo, K. Hamasaki, Y. Ishima, M. Fukagawa, M. Otagiri, and T. Maruyama A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy Kidney Int. 83 2013 446 454
93. R. Tanaka, H. Watanabe, A. Kodama, V.T. Chuang, Y. Ishima, K. Hamasaki, K.I. Tanaka, T. Mizushima, M. Otagiri, and T. Maruyama Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression J. Pharmacol. Exp. Ther. 345 2013 271 283
94. D. Sleep, G.P. Belfield, D.J. Ballance, J. Steven, S. Jones, L.R. Evans, P.D. Moir, and A.R. Goodey Saccharomyces cerevisiae strains that overexpress heterologous proteins Biotechnology 9 1991 183 187
95. D. Sleep, C. Finnis, A. Turner, and L. Evans Yeast 2 micron plasmid copy number is elevated by a mutation in the nuclear gene UBC4 Yeast 18 2001 403 421 (Pubitemid 32266192)
96. B. Ahrén Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes Nat. Rev. Drug Discov. 8 2009 369 385
97. Z.T. Bloomgarden Gut-derived incretin hormones and new therapeutic approaches Diabetes Care 27 2004 2554 2559 (Pubitemid 39281420)
98. S. Madsbad, U. Kielgast, M. Asmar, C.F. Deacon, S.S. Torekov, and J.J. Holst An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future Diabetes Obes. Metab. 13 2011 394 407
99. J.B. Bock, A. C. Bell, J. Herpst, Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia, Patent application US 2010/0227818 A1.
100. C.D. Volovat, O. Gladkov, I. Bondarenko, S. Barash, A. Buchner, N. Avisar, and P. Bias Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy J. Clin. Oncol. 30 2012 (Suppl.; abstr 9125)
101. A.A. Cordes, J.F. Carpenter, and T.W. Randolph Selective domain stabilization as a strategy to reduce human serum albumin-human granulocyte colony stimulating factor aggregation rate J. Pharm. Sci. 101 2012 2009 2016
102. A.A. Cordes, C.W. Platt, J.F. Carpenter, and T.W. Randolph Selective domain stabilization as a strategy to reduce fusion protein aggregation J. Pharm. Sci. 101 2012 1400 1409
103. C. Horn, H. Steuber, T. Weimer, W. Wormsbächer, U. Liebing, W.P. Kuo, H.J. Metzner, and S. Schulte Concept and structure model of factor VIIa albumin fusion proteins Haemophilia 16 Suppl. 4 2010 37
104. M.W. Nolte, T.C. Nichols, J. Mueller-Cohrs, E.P. Merricks, I. Pragst, S. Zollner, and G. Dickneite Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs J. Thromb. Haemost. 10 2012 1591 1599
105. E. Santagostino, C. Negrier, R. Klamroth, A. Tiede, I. Pabinger-Fasching, C. Voigt, I. Jacobs, and M. Morfini Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients Blood 120 2012 2405 2411
106. J.T. Andersen, S. Foss, V.E. Kenanova, T. Olafsen, I.S. Leikfoss, D.C. Roopenian, A.M. Wu, and I. Sandlie Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life J. Biol. Chem. 287 2012 22927 22937